Opaganib Receives FDA Rare Pediatric Disease Designation, Opening Path to Valuable Priority Review Voucher
Summary
RedHill Biopharma's drug candidate, Opaganib, has received FDA Rare Pediatric Disease Designation (RPDD) for neuroblastoma, adding to its existing Orphan Drug Designation. This follows a 6-K filing earlier today confirming the designation. The RPDD makes Opaganib eligible for a Priority Review Voucher (PRV) upon FDA approval, which could be a significant non-dilutive funding source for the company. This is a major positive regulatory development, especially given the company's recent Nasdaq delisting notice and 'going concern' warning.
At the time of this announcement, RDHL was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $0.71 to $3.31. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.